Disease therapy using dying or dead cells

Inactive Publication Date: 2005-09-15
ENLIVEX THERAPEUTICS LTD
View PDF30 Cites 33 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0052] The present invention successfully addresses the shortcomings of the presently known configurations by providing a method of treating with improved safety and effectiveness diseases associated with pathologi

Problems solved by technology

Diseases characterized by pathological immune responses include a large number of diseases which are associated with significant mortality and morbidity, and for which no satisfactory/optimal treatments are available.
Were it not for the cellular debris-removing cells of the immune system, typically macrophages, tissue and organ growth would be impossible due to a lack for space.
However, in the absence of infection and conditioned media, immature dendritic cells do not mature following uptake of apoptotic cells and as a consequence are less able to efficiently present acquired antigens.
When the immune system is deficient in recognition between self- and non-self-antigens, the result is a: state of disease, this may result in the immune system attacking one or more specific self molecules or cells leading to tissue and organ damage, resulting in autoimmune disease.
This armory has the potential to destroy healthy cells and tissues because many of the effector molecules, such as pro-inflammatory cytokines, act in a non-antigen-specific manner and also because certain pathogen-specific receptors, such as B-cell receptors (BCRs) and T-cell receptors (TCRs) may cross-react with host antigens.
Immune responses to pathogens therefore pose a potential danger to the host and immunopathology occurs with many types of infection.
However disregulation of this process may represent a mechanism of escape from immune surveillance against infections and tumors and, if inefficient, it may support persistent inflammation and autoimmunity [16, 17].
Another issue that remains unclear is the role of apopto

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Disease therapy using dying or dead cells
  • Disease therapy using dying or dead cells
  • Disease therapy using dying or dead cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment of an Autoimmune Disease (SLE) by Administration of Syngeneic Apoptotic Lymphocytes

[0185] Introductions: Autoimmune diseases, such as systemic lupus erythematosus (SLE), include numerous highly debilitating and / or lethal diseases for which there is no satisfactory or optimal therapy. An optimal strategy for treating such diseases would be to present targeted antigens to the immune system of an individual afflicted with such a disease in, such a way as to induce tolerances to such antigens by the immune system of the individual. An optimal way to achieve this goal would be to employ autologous apoptotic cells, which would obviate or minimize the necessity for administration of toxic immunosuppressive agents, the standard means of treatment in the art. While various approaches have been proposed in the prior art for using autologous cells to induce such therapeutic immune tolerance, such approaches suffer from various drawbacks, including suboptimal effectiveness, and / or fa...

example 2

Monocytes Suspended Ex-Vivo Undergo Necrosis and Produce Whereas Substrate-Adherent Ex-Vivo Monocytes Undergo Apoptosis Without Pro-Inflammatory Mediator Production: Method of Improving Prior Art Apheresis Procedures

[0200] Introduction: Immune / hematological diseases, such as graft versus host disease (GVHD), include a large number of diseases which are associated with significant mortality and morbidity, and for which no satisfactory / optimal treatments are available. In a very large number of cases the optimal strategy for treating such diseases involves performing apheresis procedures. Typically, apheresis procedures involve removing blood from an individual, separating the blood into fractions and performing therapeutic treatment of specific fractions, removing undesirable pathological fractions and reinfusing the remainder to the individual, or harvesting desired may be associated with undesirable side-effects and / or suboptimal effectiveness. Therefore, a potentially optimal str...

example 3

Therapeutic Usage of Apoptotic Lymphocytes

[0225] Apoptotic lymphocytes have an immunosuppressive, tolerizing, and anti-inflammatory effect provided they are isolated in the right way and therapeutically in the right conditions and if mixed with other cells, only in controlled way (which does not occur spontaneously in leukocytes from the blood). Described below are methods of suitably obtaining and administering apoptotic lymphocytes for treatment of various disease conditions.

[0226] Materials and Methods:

[0227] Generation of Apoptotic Lymphocytes:

[0228] 1. Isolation of up to 1 billion PBMCs from up to 500 milliliters autologous blood, or up to 10 billion PBMCs by leukocyte apheresis.

[0229] 2. Isolation of lymphocytes from PBMCs using magnetic beads conjugated to ligands of lymphocyte surface markers, or by subtraction of adherent lymphocytes.

[0230] 4. Induction of lymphocyte apoptosis by one or more of the following methods: [0231] (i) serum withdrawal-induced apoptosis; [023...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Forceaaaaaaaaaa
Surfaceaaaaaaaaaa
Login to view more

Abstract

A method of treating a disease characterized by a pathological immune response in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of a cell preparation which comprises dying or dead leukocytes, the dying or dead leukocytes being capable of suppressing the pathological immune response, thereby treating the disease in the subject.

Description

[0001] This is a continuation-in-part of U.S. patent application Ser. No. 10 / 470,536, filed Jul. 8, 2004, which is a National Phase of PCT Patent Application No. PCT / IL02 / 00089, filed Jan. 31, 2002, which claims the benefit of priority of U.S. Provisional Patent Application No. 60 / 265,127, filed Jan. 31, 2001, the contents of which are hereby incorporated by reference.FIELD AND BACKGROUND OF THE INVENTION [0002] The present invention relates to methods of using dying cells for treating diseases characterized by pathological immune responses, and to devices for preparing such dying cells. More particularly, the present invention relates to methods of using apoptotic leukocytes for treating diseases characterized by pathological immune responses, such as autoimmune diseases and transplantation related diseases, and to devices for preparing such apoptotic leukocytes. [0003] Diseases characterized by pathological immune responses include a large number of diseases which are associated w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12A61K35/15A61K35/26A61K35/28A61K39/00
CPCA61K35/15A61K35/26A61K39/0008A61K2039/515A61M1/3472C12N2500/90A61K41/0023A61M1/3486C12N5/0645C12N13/00A61M1/3681A61M1/3683A61P37/02A61P37/06
Inventor MEVORACH, DROR
Owner ENLIVEX THERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products